Fukuda Akihiro, Sato Yuji, Iwatsubo Shuji, Komatsu Hiroyuki, Nishiura Ryousuke, Fukudome Keiichi, Yamada Kazuhiro, Hara Seiichiro, Fujimoto Shouichi, Kitamura Kazuo
Circulatory and Body Fluid Regulation, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Nihon Jinzo Gakkai Shi. 2009;51(2):130-7.
A 65-year-old man was admitted to our hospital with abdominal fullness and leg edema in April 2005. Diabetes mellitus and hypertension that had been diagnosed in 1990 were well-controlled with oral hypoglucemic drug. He presented with malignant thymoma accompanied by multiple metastases in the right thoracic space in December 2000. He was treated with total thymectomy, combined with chemotherapy (cisplatin + vinorelbin) and hyperthermia. This strategy obviously reduced the tumor mass. However, CT scans showed multiple recurrences of thymoma in December 2004 and abdominal fullness and leg edema appeared shortly thereafter. Laboratory findings revealed proteinuria (over 10 g/day), hypoalbuminemia, hyperlipidemia and renal dysfunction. A kidney biopsy revealed minor glomerular abnormality. He was diagnosed with minimal change nephrotic syndrome (MCNS) complicated with the recurrence of malignant thymoma. Corticosteroid therapy was started, but dialysis was transiently required to protect against oliguric acute renal failure. Three weeks after the initiation of steroid therapy, the proteinuria was improved to less than 1.0 g/day and renal function returned to within the normal range. Subsequent corticosteroid combined with immunosuppressive therapy resulted in good control of his nephrotic syndrome (NS) without recurrence. There have been a few case reports showing NS complicated with malignant thymoma. Among these, several cases with MCNS occurred after thymectomy for malignant thymoma. Interestingly, both the thymoma mass and high pre-treatment vascular endothelial growth factor (VEGF) levels decreased as NS improved with steroid therapy. These findings suggest that VEGF also might have been associated with the onset of NS in this patient.
一名65岁男性于2005年4月因腹胀和腿部水肿入住我院。1990年诊断出的糖尿病和高血压通过口服降糖药得到良好控制。他于2000年12月被诊断为恶性胸腺瘤,伴有右胸腔多发转移。他接受了全胸腺切除术,并联合化疗(顺铂+长春瑞滨)和热疗。该治疗策略明显缩小了肿瘤体积。然而,2004年12月的CT扫描显示胸腺瘤多次复发,此后不久出现腹胀和腿部水肿。实验室检查发现蛋白尿(超过10g/天)、低白蛋白血症、高脂血症和肾功能不全。肾活检显示轻微的肾小球异常。他被诊断为微小病变肾病综合征(MCNS)合并恶性胸腺瘤复发。开始使用皮质类固醇治疗,但为预防少尿性急性肾衰竭短暂需要透析。皮质类固醇治疗开始三周后,蛋白尿改善至低于1.0g/天,肾功能恢复至正常范围。随后的皮质类固醇联合免疫抑制治疗使他的肾病综合征(NS)得到良好控制,未复发。有几例病例报告显示NS合并恶性胸腺瘤。其中,几例MCNS病例发生在恶性胸腺瘤胸腺切除术后。有趣的是,随着皮质类固醇治疗使NS改善,胸腺瘤体积和治疗前高血管内皮生长因子(VEGF)水平均下降。这些发现表明VEGF也可能与该患者NS的发病有关。